Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis

Blood

Volumn 125, Issue 17, 2015, Pages 2649-2655

  Komrokji, Rami S ^a   Seymour, John F ^b,c   Roberts, Andrew W ^d,e   Wadleigh, Martha ^f   To, L Bik ^g   Scherber, Robyn ^h   Turba, Elyce ^a   Dorr, Andrew ⁱ   Zhu, Joy ⁱ   Wang, Lixia ^j   Granston, Tanya ^j   Campbell, Mary S ^j   Mesa, Ruben A ^h  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e ROYAL MELBOURNE HOSPITAL   (Australia)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g ROYAL ADELAIDE HOSPITAL   (Australia)

^h MAYO CLINIC   (United States)

ⁱ Singapore Science Park II   (Singapore)

^j CTI BioPharma   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIANEMIC AGENT; ANTIDIARRHEAL AGENT; ANTIEMETIC AGENT; ASPARTATE AMINOTRANSFERASE; CLOPIDOGREL; HEMOGLOBIN; ONDANSETRON; PACRITINIB; TRIACYLGLYCEROL LIPASE; WARFARIN; 11-(2-PYRROLIDIN-1-YLETHOXY)-14,19-DIOXA-5,7,26-TRIAZATETRACYCLO(19.3.1.1(2,6).1(8,12))HEPTACOSA-1(25),2(26),3,5,8,10,12(27),16,21,23-DECAENE; BRIDGED COMPOUND; CD135 ANTIGEN; JANUS KINASE 2; PYRIMIDINE DERIVATIVE;

ABDOMINAL PAIN; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ALOPECIA; ANEMIA; ANTICOAGULANT THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; ATRIAL FIBRILLATION; BLEEDING; BONE PAIN; CANCER CONTROL; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CYTOPENIA; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ENGRAFTMENT; EPISTAXIS; ERYTHROCYTE TRANSFUSION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FLATULENCE; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; HYPERBILIRUBINEMIA; HYPERSENSITIVITY; HYPERURICEMIA; HYPONATREMIA; INSOMNIA; INTERNATIONAL NORMALIZED RATIO; LEUKOPENIA; LILLE SCORE; LYMPHOCYTOPENIA; MALE; MULTICENTER STUDY; MUSCULOSKELETAL PAIN; MYELOFIBROSIS; NAUSEA; NIGHT SWEAT; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PHYSICAL EXAMINATION; PHYSICAL INACTIVITY; PRIORITY JOURNAL; PRURITUS; QT PROLONGATION; RECOMMENDED DRUG DOSE; SATIETY; SCORING SYSTEM; SEPTIC SHOCK; SIDE EFFECT; SPLEEN SIZE; SPLENOMEGALY; SUBDURAL HEMATOMA; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VERY ELDERLY; VOMITING; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMPLICATION; DRUG EFFECTS; MIDDLE AGED; PATHOLOGY; PRIMARY MYELOFIBROSIS; SPLEEN;

ADULT; AGED; AGED, 80 AND OVER; BRIDGED COMPOUNDS; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; PRIMARY MYELOFIBROSIS; PYRIMIDINES; SPLEEN; SPLENOMEGALY;

EID: 84928901823     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-02-484832     Document Type: Article

References (21)

1. Komrokji RS, Verstovsek S, Padron E, List AF. Advances in the management of myelofibrosis. Cancer Contr. 2012;19(4 suppl):4-15.
2. Baxter EJ, Scott LM, Campbell PJ, et al; Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054-1061.
3. James C, Ugo V, Le Couédic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144-1148.
4. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005; 352(17):1779-1790.
5. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387-397.
6. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895-2901.
7. Lippert E, Boissinot M, Kralovics R, et al. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood. 2006;108(6):1865-1867.
8. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379-2390.
9. Quintás-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010;115(15):3109-3117.
10. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799-807.
11. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787-798.
12. Seymour F, To B, Goh A, et al. First report of the phase-I study of the novel oral JAK2 inhibitor SB1518 in patients with myelofibrosis [abstract]. Haematologica. 2010;95(suppl 2):472. Abstract 1144.
13. Mesa RA, Schwager S, Radia D, et al. The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res. 2009;33(9):1199-1203.
14. Tefferi A, Barosi G, Mesa RA, et al; IWG for Myelofibrosis Research and Treatment (IWG-MRT). International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood. 2006;108(5):1497-1503.
15. Verstovsek S, Odenike O, Scott B, et al. Phase I dose-escalation trial of SB1518, a novel JAK2/FLT3 inhibitor, in acute and chronic myeloid diseases, including primary or post-essential thrombocythemia/polycythemia vera myelofibrosis [abstract]. Blood. 2009;114(22). Abstract 3905.
16. Younes A, Romaguera J, Fanale M, et al. Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes. J Clin Oncol. 2012;30(33):4161-4167.
17. Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29(4):392-397.
18. Dingli D, Schwager SM, Mesa RA, Li CY, Tefferi A. Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia: a simple CBCbased scoring system. Cancer. 2006;106(3):623-630.
19. Huang J, Li CY, Mesa RA, et al. Risk factors for leukemic transformation in patients with primary myelofibrosis. Cancer. 2008;112(12):2726-2732.
20. Patnaik MM, Caramazza D, Gangat N, Hanson CA, Pardanani A, Tefferi A. Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival. Eur J Haematol. 2010;84(2):105-108.
21. Tefferi A, Lasho TL, Jimma T, et al. One thousand patients with primary myelofibrosis: the mayo clinic experience. Mayo Clin Proc. 2012;87(1):25-33.